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Abstract 
Context: While the consequences of severe iodine deficiency are beyond doubt, the effects of mild-to-
moderate iodine deficiency in pregnancy on child neurodevelopment are less well established. 
Objective: To study the association between maternal iodine status during pregnancy and child IQ and 
to identify vulnerable time-windows of exposure to suboptimal iodine availability. 
Design: Meta-analysis of individual-participant data from three prospective population-based birth 
cohorts: Generation R (The Netherlands), INMA (Spain), and ALSPAC (United Kingdom); pregnant 
women were enrolled between 2002-2006, 2003-2008, and 1990-1992, respectively.   
Setting: General community. 
Participants: 6180 mother-child pairs with measures of urinary iodine and creatinine concentrations in 
pregnancy and child IQ. Exclusion criteria were multiple pregnancy, fertility treatment, medication 
affecting the thyroid, and pre-existing thyroid disease. 
Intervention(s): None. 
Main Outcome Measure: Child non-verbal and verbal IQ assessed at 1.5-8 years of age. 
Results: There was a positive curvilinear association of the urinary iodine-to-creatinine ratio (UI/Creat) 
with mean verbal IQ only. UI/Creat < 150 µg/g was not associated with lower non-verbal IQ [-0.6 
points, 95% CI -1.7 to 0.4, P=0.246] or lower verbal IQ [-0.6, 95% CI -1.3 to 0.1, P=0.082]. Stratified 
analyses showed that the association of UI/Creat with verbal IQ was only present up to 14 weeks of 
gestation. 
Conclusions: Fetal brain development is vulnerable to mild-to-moderate iodine deficiency, particularly 
in the first trimester. Our results show that any potential randomized, controlled trial investigating the 
effect of iodine supplementation in mild-to-moderate iodine deficient women on child 
neurodevelopment, should start with supplementation not later than the first trimester. 
 
Keywords: thyroid; cognition; neurodevelopment; Generation R; INMA; ALSPAC  
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Introduction 
Iodine is an essential trace element required for the production of thyroid hormones; optimal thyroid 
hormone availability is important for normal fetal brain development (1,2). During pregnancy there is a 
higher demand for maternal iodine intake (3,4). This is due to: i) the increased maternal thyroid 
hormone synthesis required to ensure adequate thyroid hormone availability to the fetus, ii) greater 
urinary iodine loss due to an increased glomerular filtration rate, and iii) placental transfer of iodine to 
the fetus to facilitate fetal thyroid hormone production. While severe iodine deficiency is no longer 
common in Europe, mild-to-moderate iodine deficiency is still common, especially in pregnant women 
(5). Severe iodine deficiency in pregnancy results in a higher risk of goiter, hypothyroidism, and mental 
retardation in the offspring (6). However, the consequences of mild-to-moderate iodine deficiency in 
pregnancy on child neurodevelopment are less well established (4).  
Mild-to-moderate iodine deficiency or low iodine intake during pregnancy has been associated 
with adverse child neurodevelopmental outcomes observed in some (7–13), but not all studies (14–16). 
Differences in results between studies might be related to methodological differences (e.g. 
measurement of iodine status, selected reference group and available data on confounders), the age of 
assessment of the neurodevelopmental outcome of interest, the timing of the iodine measurements, and 
the relative severity of iodine deficiency in the population. While the main focus in the literature has 
been on the effects of iodine deficiency, some studies have suggested adverse effects of supplementary 
intake or excess iodine on either maternal thyroid function (17,18), fetal thyroid function (19,20), or 
child neurodevelopment (10,15,16).  
International health authorities have similar recommendations to ensure optimal iodine status in 
pregnancy (21–23). It is universally recognized that any necessary iodine supplementation should be 
commenced before, or as early as possible in pregnancy to achieve adequate iodine intake, owing to the 
susceptibility of the fetal brain to iodine deficiency (23). However, whether the effect of iodine on child 
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cognition varies during different stages of pregnancy is unknown. We therefore assessed the 
association between maternal iodine status in pregnancy and child IQ across three cohorts of differing 
iodine status, and investigated potential effect modification by gestational age.  
 
Material and Methods  
Study design and populations 
This study was embedded in three cohort studies: Generation R (The Netherlands), INfancia y Medio 
Ambiente Project (INMA; Spain, three regions), and the Avon Longitudinal Study of Parents and 
Children (ALSPAC, United Kingdom). Their study designs have been described elsewhere (24–27); 
the ALSPAC study website contains details of all the data that are available through a fully searchable 
data dictionary and variable search tool (28). For the current study, mother-child pairs were included if 
a measure of urinary iodine and creatinine concentration during pregnancy, and child IQ were 
available. Exclusion criteria were multiple pregnancy, fertility treatment, medication affecting the 
thyroid and pre-existing thyroid disease. Ethical approval was obtained from: the Medical Ethical 
Committee of the Erasmus Medical Center (Generation R), Ethical Committee of the Municipal 
Institute of Medical Investigation and by the Ethical Committee of the hospitals involved in the study 
(INMA), and the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees; 
approval by participants and/or parents or guardians of the children was given by signed informed-
consent. 
 
Maternal iodine status  
Urinary iodine concentration (UIC) and creatinine concentration were measured in spot urine samples 
stored at -20°C after collection. As part of this study, additional urine samples were analysed for iodine 
and creatinine concentration and existing measurements from each cohort (7,19,29) were also included. 
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The additional measurements were performed in the same laboratories as where the existing 
measurements were performed. The laboratories were registered with EQUIP and used certified 
reference materials (Seronorm urine Levels one and two, Nycomed, Norway) for the verification of 
results. In Generation R, UIC was measured by the Sandell-Kolthoff method. In INMA, UIC was 
measured using paired-ion reversed-phase, high-performance liquid chromatography with 
electrochemical detection at a silver working electrode (Waters Chromatography, Milford, MA). In 
ALSPAC, UIC was measured on a dynamic reaction cell inductively-coupled plasma mass 
spectrometer. Urinary creatinine concentration was determined by the Jaffe rate method in all cohorts. 
More information on the measurement methods and the variability between assays can be found in the 
Supplemental material (30, page 2).  
In a subset of women repeated measures of urinary iodine and creatinine were available; we 
used the earliest available sample as an indicator of iodine status. The urinary iodine-to-creatinine ratio 
(UI/Creat) was used as a measure of iodine status. Due to possible contamination of UIC by the use of 
iodine-containing test strips in ALSPAC (31), UIC above 500 µg/L and/or UI/Creat >700 µg/g were 
excluded from the analyses in this cohort (N=363). These cut-offs were based on previous work in 
ALSPAC and from other studies of pregnant women in the United Kingdom (7,32,33). We grouped 
women’s results by UI/Creat: (i) <150 µg/g, (ii) 150 to < 500 µg/g, and (iii)  ≥500 µg/g; based on 
WHO classification these groups broadly relate to iodine deficiency, sufficiency, and excess, 
respectively.  
 
Maternal thyroid function  
Thyroid stimulating hormone (TSH) and free thyroxine (FT4) were measured according to different 
methodologies between cohorts, which are described in detail elsewhere (34–36). For the analysis, FT4 
and TSH concentrations were logarithmically transformed and cohort-specific SD scores were 
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calculated with a mean of 0 and a SD of 1 based on the data of TPOAb-negative women (TPOAb 
measurements were available in Generation R and ALSPAC). A TPOAb titre ≥ 60 IU/mL and ≥ 6 
IU/mL was considered as positive in Generation R and ALSPAC, respectively. These cut-offs were 
determined by the assay manufactures.  
 
Non-verbal and verbal IQ 
In Generation R, non-verbal IQ was assessed at a median age of 5.9 years using a subset of the Snijders 
Oomen Nonverbal Intelligence Test (2.5-7-Revised) (37) and verbal IQ was estimated by the short 
form of the McArthur Communicative Development Inventory (38) at a median age of 1.5 years. In 
INMA, non-verbal and verbal IQ were assessed at a median age of 4.6 years using McCarthy Scales of 
Children´s Abilities (39). In ALSPAC, non-verbal and verbal IQ were assessed at a median age of 8.6 
years using the Wechsler Intelligence Scale for Children, 3rd UK edition (40). Except for verbal IQ 
ascertainment in Generation R, which was a parental questionnaire, all other measurements were 
performed by psychologists or trained staff. To homogenize the different scores, raw cohort-specific 
scores were standardized to a mean of 100 and a SD of 15. Children with IQ scores below 50 or above 
150 (n=3) were considered as outliers and excluded from analyses. Suboptimal IQ was defined as an IQ 
score below 85.  
 
Potential confounding variables 
Information on maternal age, educational level (low, middle, high), ethnicity/country of birth (cohort-
specific categories), parity (zero, one, two or more), pre-pregnancy body mass index, and smoking 
during pregnancy (never smoked, smoked in the beginning or until pregnancy confirmed, continued 
smoking) was collected by questionnaires administered during pregnancy. Gestational age at urine 
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sampling was defined using ultrasound or last menstrual period. Child sex and age at time of the IQ 
assessment was obtained during the study visits.  
 
Statistical Analyses  
UI/Creat was not normally distributed and was therefore transformed using the natural logarithm; back-
transformed values are shown in plots for better interpretation. We studied the associations of UI/Creat 
with child non-verbal and verbal IQ by using a one-step and a two-step approach. In the one-step 
approach, data from the cohorts were pooled and we performed standard multivariable linear regression 
models with and without a quadratic term to investigate the possible non-linear nature of the 
associations. Non-linearity was also investigated by using ordinary least-squares linear regression 
models with restricted cubic splines with three knots. With ANOVA we tested the null hypothesis that 
child mean IQ was similar across the full range of the natural logarithm of UI/Creat. The decision for 
linear regression models instead of multilevel models for the one-step analyses was made because we 
found no difference between multilevel models with random intercepts and/or slope per cohort versus 
standard linear regression correcting for cohort (e.g. cohort-specific variable ethnicity/country of birth) 
when assessed using the Akaike information criterion and log-likelihood tests. In the two-step approach 
we first studied the associations UI/Creat < 150 µg/g and UI/Creat ≥ 500 µg/g with child IQ by using 
linear regression models in each cohort separately. In these analyses the reference group consisted of 
women with UI/Creat 150-500 µg/g. We then combined the cohort-specific effect estimates using 
random effects meta-analyses.  
  Potential effect modification according to gestational age was analyzed by adding a product 
interaction term between UI/Creat and gestational age to the one-step approach models. Due to the 
known constraints of statistical power for interaction analyses, a P-value below 0.15 for interaction 
terms was used to screen for potential relevant modification (41). We further quantified potential 
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relevant differences by performing stratified analyses by tertile of gestational age (≤12 weeks, >12 to 
≤14 weeks, and >14 weeks). We also studied associations with suboptimal IQ (score<85) by combining 
cohort-specific estimates from logistic regression models into random effects meta-analyses.  
  Sensitivity analyses aimed to study: i) the associations of UI/Creat with verbal IQ in mother-
child pairs from INMA and ALSPAC only, as verbal IQ was assessed at a pre-school age in Generation 
R; ii) the association between UI/Creat and maternal TSH and FT4 SD scores within the ± 4 SD range 
around the mean, as TSH and FT4 values outside this range were considered as outliers (n=19 for TSH, 
n=5 for FT4); and iii) whether the association between UI/Creat and IQ could potentially be explained 
by maternal thyroid function by adjusting for FT4 and TSH in the models.    
  Heterogeneity between cohorts was assessed using the Cochran Q test and the I2 statistic (42). 
All models were adjusted for the potential confounding variables. However, due to collinearity between 
maternal ethnicity/country of birth, child age at IQ ascertainment, and cohort, we only adjusted for 
maternal ethnicity/country of birth in the one-step approach models.  
We applied inverse probability weighting to take into account the potential differential loss to 
follow-up (eTable 1) (30), i.e. to account for selection bias that potentially arises when only the 
population with available data on iodine status and child IQ is included as compared to a full initial 
cohort recruited at pregnancy (43). Briefly, we used information available for all participants at 
recruitment to predict the probability of participation in the study, and used the inverse of those 
probabilities as weights in the analyses so that results would be representative for the initial populations 
of the cohorts. Additionally, missing values in the potential confounding variables were imputed using 
chained equations (44). A total of 25 datasets were generated. A P-value < 0.05 was defined as 
statistically significant. Statistical analyses were performed in STATA (version 14.0; StataCorporation, 
College Station, TX) and R statistical software (version 3.3.2, package rms).  
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Results 
The final study population consisted of 6180 mother child-pairs (Figure 1). The median UIC (UI/Creat) 
was 159 µg/L (214 µg/g) in Generation R (adequate intake), 128 µg/L (152 µg/g) in INMA (mild 
deficiency), and 96 µg/L (124 µg/g) in ALSPAC (moderate deficiency; Table 1). Iodine status was 
determined at a median (IQR) gestational age of 13.1 (12.1-14.8), 13.0 (12.4-14.1) and 12.0 (8.0-16.0) 
weeks in Generation R, INMA, and ALSPAC, respectively.  
 
Non-verbal IQ 
Using pooled data in the one-step approach, we observed a positive linear association between the 
UI/Creat and mean non-verbal IQ (Figure 2a and eTable 2) (30), although this association was not 
statistically significant. Using the two-step approach where we combined cohort-specific effect 
estimates using random effects meta-analysis, neither UI/Creat < 150 µg/g nor UI/Creat ≥ 500 µg/g 
was associated with non-verbal IQ [-0.6 points, Confidence Interval (CI) -1.7 to 0.4, P=0.246 and -1.1 
points, 95%CI -4.2 to 2.0, P=0.478] (Figure 2b and Figure 2c). UI/Creat was not associated with 
suboptimal non-verbal IQ (eFigure 1) (30).  
 
 
Verbal IQ 
Using the one-step approach, we observed a positive curvilinear association between UI/Creat and 
verbal IQ (Figure 3a and eTable 2) (30). There was a positive linear association when excluding the 
measures in pre-school children from Generation R. Using the two-step approach, neither UI/Creat < 
150 µg/g nor UI/Creat ≥ 500 µg/g was associated with verbal IQ (-0.6 points, 95% CI -1.3 to 0.1, 
P=0.082 and -0.6 points, 95% CI -2.6 to 1.4, P=0.552, respectively) (Figure 3c and 3d) or suboptimal 
verbal IQ (eFigure 1) (30).  
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Effect modification according to gestational age 
The continuous association of UI/Creat with non-verbal IQ did not differ according to gestational age 
at measurement (P for interaction term=0.306). By contrast, we identified possible effect modification 
by gestational age in the association with verbal IQ (P for interaction term=0.078). Stratification by 
tertile of gestational age showed a positive curvilinear association of UI/Creat with mean child verbal 
IQ with an overall effect of roughly 5 IQ points during the first 12 weeks of pregnancy (Figure 4a and 
eTable 3) (30). Furthermore, there was a positive linear association between UI/Creat and mean child 
verbal IQ during the 12th to 14th week of pregnancy with an overall effect of roughly 3 IQ points 
(Figure 4b). This association was no longer present after the 14th week of pregnancy (Figure 4c).  
 
Iodine status and thyroid function 
UI/Creat was not associated with TSH (0.007, 95 CI% -0.044 to 0.058, P=0.789) or with FT4 (-0.044, 
95 CI% -0.092 to 0.005, P=0.079). The association did not change between UI/Creat and child non-
verbal or verbal IQ after adjusting for TSH and/or FT4; there was also no sign of effect modification by 
TSH or FT4 (data not shown).  There was no association of UI/Creat with TSH and FT4 in TPOAb 
negative women only.  
 
Discussion 
This meta-analysis of individual-participant data showed that a lower UI/Creat during pregnancy was 
associated with lower verbal IQ. The association of UI/Creat with verbal IQ was only seen up to the 
start of the second trimester (up to the 14th week of gestation). By contrast, we observed no associations 
between IQ and UI/Creat below 150 µg/g or above 500 µg/g.  
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Only a few of the previous single-centre studies, i.e., the Generation R and ALSPAC cohort 
studies, focused on child non-verbal IQ (7,14). They found no association between UI/Creat < 150 µg/g 
and non-verbal IQ. It was suggested that iodine deficiency in the Generation R cohort might not have 
been severe enough for an association to be identified(14). After combining these two cohorts of 
contrasting iodine status with a third mildy-deficient population (INMA), there was still no effect of 
iodine deficiency on non-verbal IQ.  
Our meta-analysis using pre-defined cutoffs showed that UI/Creat < 150 µg/g was not 
associated with lower verbal IQ. The estimates we found for ALSPAC are in contrast to the strong 
negative association of maternal UI/Creat < 150 µg/g  in the first trimester (defined as ≤13 weeks 
gestation) with child verbal IQ found in a previously published study from that cohort (fully adjusted: -
2.9, 95CI% -5.0 to -0.8, P=0.006) (7). However, there are a few important differences between the 
studies. Compared to the previous publication, the ALSPAC data in our study included a larger number 
of mother-child pairs (2980 vs. 958), fewer iodine-deficient women [1831 (61.4%) vs. 646 (67.4%)], a 
study population with a higher UI/Creat [median UI/Creat (IQR): 124 (82-199) vs. 110 (74-170)], and 
most notably, a higher number of mothers with iodine status measured after the first trimester [1135 
(38%) vs. 0 (0%); median gestational age (IQR): 12 (8-16) vs. 10.0 (9-12) weeks]. Additionally, we 
have adjusted our analysis for a more stringent selection of variables. Comparison between study 
populations and additional analysis of the association between UI/Creat < 150 µg/g and a verbal IQ 
score in the bottom quartile in the whole cohort and in samples ≤ 13 weeks gestation are described in 
eTable 4 and 5 (30).  
The importance of iodine status in the preconceptional stage for child IQ has recently been 
shown (45). In early pregnancy the fetus is fully dependent on the placental transfer of thyroid hormone 
to support the crucial processes of brain development (2). There is a need for optimal iodine supply 
from the initiation of conception implying that sufficient intrathyroidal iodine stores at the 
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preconception stage may well be critical. Indeed, our results suggest that the fetus is particularly 
sensitive to suboptimal iodine status in the early stages of pregnancy (e.g. ≤14 week of gestation) for 
optimal development of verbal IQ. Effects on verbal IQ could possibly be explained by the impact of 
mild iodine deficiency, via thyroid hormone, on the auditory system (13,46). In our study, we did not 
find evidence that the association between UI/Creat and verbal IQ was mediated via maternal thyroid 
function. Possible explanations could be that urinary iodine excretion is a highly volatile and crude 
measurement of individual iodine status and/or a crude marker of thyroidal iodine availability. 
Alternatively, it is also possible that the effects are (in part) mediated via fetal thyroid function.  
This study confirms that low iodine status is associated with a reduction in verbal IQ scores, 
putting these children potentially at risk of poorer academic achievement (47). Furthermore, on a 
national level, our findings may have implications, for example by negatively affecting economic 
growth (48). However, evidence for the benefits of supplementation of mild-to-moderate iodine 
deficient women on child neurodevelopment is still inconclusive (11,15,16,49–53). A recent 
randomized, placebo-controlled trial showed no benefit on child non-verbal or verbal IQ of daily 
supplementation with 200 µg iodine (as potassium iodide) of mildly iodine-deficient women (52). In 
addition to the already-mentioned limitations of that trial (54), our results provide an additional 
explanation for the null finding; the trial randomized women up to 14 weeks of gestation, while we 
showed that maternal iodine status is particularly important in the first trimester. Although our study 
needs replication, it suggests that the trial might have missed a critical period of vulnerability in iodine-
deficient women. Our results clearly suggest that further randomized controlled trials should start with 
iodine supplementation early in the first trimester, or preferably even before pregnancy.  
The strengths of our study are the following: the same approach of analysis and harmonization 
of potential confounding variables across cohorts optimized comparisons; advanced statistical methods 
were used to overcome selection bias due to loss to follow up and missing data; UI/Creat was used as a 
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marker of iodine status - this has been shown to be a more valid measure of iodine excretion when used 
in the same groups of age and sex (55), though we recognize that a single measure may not be 
reflective of overall iodine status in an individual. A limitation of the study is that the assessment of IQ 
was performed with different tools at different ages. Nevertheless, the tools measured the same 
construct (non-verbal or verbal IQ) and the standardization of IQ scores in each cohort facilitated 
comparison of results across cohorts. Sensitivity analysis in older children only (e.g. excluding children 
from Generation R), thus reducing the age range at which verbal IQ was assessed, confirmed the 
association between UI/Creat and verbal IQ. Another limitation is that UIC was measured in different 
laboratories using different assays; it is known that urinary iodine measurements vary between 
laboratories (56). We used laboratories that were registered with EQUIP and the use of certified 
reference materials enabled us to ensure the accuracy of results. 
  In conclusion, this study confirms that iodine status in pregnancy is associated with child IQ 
and results indicate that the development of verbal IQ of the fetus is particularly vulnerable to 
suboptimal iodine concentration during early pregnancy up until the start of second trimester. As such, 
our results suggest that iodine supplementation after the first fourteen weeks of pregnancy could be 
outside of the critical period during which iodine availability affects fetal brain development. However, 
further studies should replicate these data and study the effects of iodine supplementation.  
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Table 1 Population characteristics 
 
Generation R (n=1931) INMA (n=1269) ALSPAC (n=2980) 
 
n  values n  values n  values 
Offspring neurodevelopment, No. (%)   
 
 
 
 
 
Suboptimal non-verbal IQa 1540 175 (11.4) 1269 216 (17.0) 2979 479 (16.1) 
  Suboptimal verbal IQa 1618 279 (17.2) 1269 211 (16.6) 2977 480 (16.1) 
Female sex, No. (%) 1931 963 (49.9) 1268 632 (49.8) 2980 1514 (50.8) 
Iodine status  1931 
 
1269 
 
2980 
 
  UI/Creat, µg/g, median (IQR)  214 (143-308)  152 (96-258)  124 (82-199) 
  UI/Creat < 150 µg/g, No. (%)  531 (27.5)  623 (49.1)  1831 (61.4) 
  UI/Creat > 500 µg/g, No. (%)  97 (5.0)  52 (4.1)  81 (2.7) 
  UIC, µg/L, median (IQR)  159 (90-275)  128 (75-213)  96 (57-153) 
Gestational age at urine sampling, weeks 1931  1267  2980  
  Median (IQR)  13.1 (12.1-14.8)  13.0 (12.4-14.1)  12.0 (8.0-16.0) 
  Range (min-max)  6.1-30.5  8.6-39.4  1.0-42.0 
  > 20th week of gestation, No. (%)  66 (3.4)  130 (10.2)  211 (7.1) 
Maternal thyroid function   
 
 
 
 
 
  TSH, mIU/L, median (IQR) 1719 1.29 (0.79-1.95) 1227 1.25 (0.85-1.80) 1102 0.97 (0.64-1.38) 
  FT4, pmol/L, median (IQR) 1728 14.6 (12.9-16.5) 1229 10.6 (9.7-11.6) 1108 16.2 (14.9-17.7) 
  TPOAb positivity, No. (%) 1737 98 (5.6) NA NA 1111 146 (13.1) 
  Gestational age, weeks, mean (SD) 1733 13.3 (1.9) 1228 13.2 (1.4) 1118 10.3 (2.7) 
Educational level, No. (%)  1835 
 
1265 
 
2888 
 
  Low  154 (8.4)  270 (21.3)  573 (19.8) 
  Middle  760 (41.4)  525 (41.5)  1810 (62.7) 
  High  921 (50.2)  470 (37.2)  505 (17.5) 
Maternal ethnicity/country of birth, No. (%)  1803 
 
1266 
 
2877 
 
  Spanish  NA  1184 (93.5)  NA 
  Latin-American  NA  56 (4.4)  NA 
  European/other  NA  26 (2.1)  NA 
  Dutch  1012 (53.2)  NA  NA 
  Indonesian  69 (3.6)  NA  NA 
  Cape Verdean  58 (3.1)  NA  NA 
  Moroccan  115 (6.0)  NA  NA 
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Table 1 Population characteristics (continued) 
 
 Generation R (n=1931) INMA (n=1269) ALSPAC (n=2980) 
 n values n values n values 
  Surinamese  154 (8.1)  NA  NA 
  Turkish  170 (9.0)  NA  NA 
  Other, non-western    150 (7.9)  NA  NA 
  Other, western  174 (9.1)  NA  NA 
  White  NA  NA  2841 (98.7) 
  Non-white  NA  NA  36 (1.3) 
Maternal age, years, mean (SD) 1931 30.5 (4.8) 1257 31.6 (3.9) 2980 28.6 (4.5) 
Parity, No. (%) 1931  1267  2877  
  0  1121 (58.1)  727 (57.4)  1346 (46.8) 
  1  564 (29.2)  458 (36.1)  992 (34.5) 
  ≥2  246 (12.7)  82 (6.5)  539 (18.7) 
Smoking during pregnancy, No. (%) 1744 
 
1254 
 
2926 
 
  Never   1319 (75.6)  870 (69.4)  2434 (83.2) 
  In the beginning of pregnancy  168 (9.6)  168 (13.4)  125 (4.3) 
  Continued   257 (14.7)  216 (17.2)  367 (12.5) 
Pre-pregnancy BMI, kg/m2, median (IQR) 1694 22.6 (20.8-25.2) 1269 22.5 (20.8-25.0) 2713 22.2 (20.5-24.4) 
Abbreviations: NA, not applicable; BMI, Body Mass Index. Values are based on unimputed data. a Suboptimal defined as an IQ score<85 
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Figure 1 Flowchart of the selection of the study population. 
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Figure 2 Association of maternal iodine status in pregnancy with child non-verbal IQ. 
a) continuous association, depicted as the mean child non-verbal IQ (black line) with 95% confidence 
interval (grey area) using pooled data. Models are adjusted for gestational age, child sex, maternal 
ethnicity/country of birth, maternal education, parity, maternal age, pre-pregnancy BMI, and smoking 
during pregnancy. The p-value was provided by an ANOVA test of the null hypothesis that child mean 
non-verbal IQ was similar across the whole range of the natural logarithm of UI/Creat. Forest plots, b) 
UI/Creat < 150 µg/g (“deficiency”), and c) UI/Creat ≥500 µg/g (“excess”), compared to the reference 
group of UI/Creat ≥150 to <500 µg/g (“sufficient”) depicted as effect estimate (dot) with 95% 
confidence interval per cohort, and overall, as estimated by random-effects meta-analysis (diamond). 
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Figure 3 Association of maternal iodine status during pregnancy with child verbal IQ.  
a) continuous association, depicted as the mean child verbal IQ (black line) with 95% confidence 
interval (grey area), using pooled data. Models are adjusted for gestational age, child sex, maternal 
ethnicity/country of birth, maternal education, parity, maternal age, pre-pregnancy BMI, and smoking 
during pregnancy. The p-value was provided by an ANOVA test of the null-hypothesis that child mean 
verbal IQ was similar across the whole range of the natural logarithm of UI/Creat. Forest plots,  b) 
UI/Creat < 150 µg/g (“deficiency”), and c) UI/Creat ≥500 µg/g (“excess”), compared to the reference 
group of UI/Creat ≥150 to <500 µg/g (“sufficient”),  depicted as effect estimate (dot) with 95% 
confidence interval per cohort and overall as estimated by random-effects meta-analysis (diamond).  
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Figure 4 Association of maternal iodine status during pregnancy with child verbal IQ, stratified 
by tertiles of gestational age.  
Continuous association, depicted as the mean child verbal IQ (black line) with 95% confidence interval 
(grey area) restricted to: a) the first 12 weeks of gestation (lowest tertile, median UI/Creat 116 µg/g, 
N=2209), b) from week 12 to week 14 of gestation (middle tertile, median UI/Creat 147 µg/g, 
N=1776), and c) later than week 14 of gestation (highest tertile, median UI/Creat 157 µg/g. N=1879). 
Models are adjusted for gestational age, child sex, maternal ethnicity/country of birth, maternal 
education, parity, maternal age, pre-pregnancy BMI, and smoking during pregnancy. The p-value was 
provided by an ANOVA test of the null hypothesis that child mean verbal IQ was similar across the 
whole range of the natural logarithm of UI/Creat. 
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Methods of urinary iodine measurements 
In Generation R, urinary iodine was measured by the Sandell-Kolthoff method. Iodine calibration was 
performed using certified reference materials (CRM) Seronorm urine Levels one and two (Nycomed, 
Norway), and four EQUIP samples certified for urinary iodine concentration (Centers for Disease 
Control and Prevention, USA). At a level of 1.7 µmol/l iodine the within-assay CV was 5.1% and the 
between-assay CV was 14.3% (n= 30). In INMA, urinary iodine was measured using paired-ion 
reversed-phase, high-performance liquid chromatography (HPLC) with electrochemical detection at a 
silver working electrode (Waters Chromatography, Milford, MA). The accuracy of the results was 
verified using the CRM Seronorm urine Levels one and two (Nycomed, Norway), and internal quality 
control samples. Within run precision was 4.5% relative standard deviation (RSD) at 50 μg/L, 3.2% at 
100 μg/L and 2.0% at 300 μg/L. Between run precision was 7.9% RSD at 50 μg/L, 3.5% at 100 μg/L 
and 2.5 % at 300 μg/L. In ALSPAC, iodine (127I) was measured on a dynamic reaction cell inductively-
coupled plasma (ICP) mass spectrometer. The accuracy of the results was verified using the CRM 
Seronorm urine Levels one and two (Nycomed, Norway), and accuracy was also monitored by 
measurement of EQUIP samples at regular intervals throughout the analysis. Within run precision was 
0.83% RSD at 42 µg/L, 2.47% at 84 µg/L, 0.56% at 149 µg/L and 2.01% at 297 µg/L. Between run 
precision was 8.69% RSD at 42 µg/L, 6.54% at 84 µg/L, 7.2% at 149 µg/L and 6.8% at 297 µg/L. 
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eTable 1 Distribution and comparison of maternal and child characteristics in the included and excluded population 
 
Generation R INMA ALSPAC 
 included       
(n=1931) 
not included 
(n=7818) 
P-value 
Included     
(n=1269) 
not included 
(n=881) 
P-value 
Included   
(n=2980) 
not included 
(n=11752) 
P-
value 
Female sex, n(%) 963 (49.9) 3846 (49.2) 0.605 632 (49.8) 348 (46.5) 0.150 1514 (50.8) 5312 (47.6) 0.002 
Educational level, n(%)                  
    Low 154 (8.4) 791 (12.0) 
<0.001 
270 (21.3) 293 (34.4) 
<0.001 
573 (19.8) 3183 (33.1) 
<0.001     Middle 760 (41.4) 3117 (47.2) 525 (41.5) 337 (39.6) 1810 (62.7) 5318 (55.4) 
    High 921 (50.2) 2692 (40.8) 470 (37.2) 221 (26.0) 505 (17.5) 1104 (11.5) 
Maternal ethnicity/country 
of birth, n(%)      
 
    
 
    
 
    Spanish NA NA  
 
 
 
 
0.001 
1184 (93.5) 731 (85.8) 
 
 
<0.001 
 
 
 
 
 
 
 
 
 
 
 
NA NA  
 
 
 
<0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Latin-american NA NA 56 (4.4) 80 (9.4) NA NA 
    European/other NA NA 26 (2.1) 41 (4.8) NA NA 
    Dutch 1012 (53.2) 3490  (49.5) NA NA NA NA 
    Indonesian 69 (3.6) 198 (2.8) NA NA NA NA 
    Cape verdian 58 (3.1) 314 (4.5) NA NA NA NA 
    Moroccan 115 (6.0) 487 (6.9) NA NA NA NA 
    Surinamese 154 (8.1) 636 (9.0) NA NA NA NA 
    Turkish 170 (9.0) 617 (8.7) NA NA NA NA 
    Other, non-western   150 (7.9) 724 (10.3) NA NA NA NA 
    Other, western 174 (9.1) 589 (8.3) NA NA NA NA 
    White NA NA NA NA 2841 (98.7) 9234 (97.0) 
    Non-white NA NA NA NA 36 (1.3) 290 (3.0) 
Maternal age, years, mean 
(SD) 
30.5 (4.8) 29.8 (5.5) <0.001 31.6 (3.9) 30.7 (4.8) <0.001 28.6 (4.5) 26.9 (5.1) <0.001 
Parity, n(%)           
   0 1121 (58.1) 3986 (51.8) 
<0.001 
 
727 (57.4) 441 (51.8) 
0.018 
1346 (46.8) 4527 (44.2) 
0.018    1 564 (29.2) 2231 (29.0) 458 (36.1) 335 (39.4) 992 (34.5) 3596 (35.1) 
   ≥2 246 (12.7) 1480 (19.2) 82 (6.5) 75 (8.8) 539 (18.7) 2124 (20.7) 
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eTable 1 Distribution and comparison of maternal and child characteristics in the included and excluded population (continued) 
 
 
 
 
 
 
 
 
 Generation R INMA ALSPAC 
 included       
(n=1931) 
not included 
(n=7818) 
P-value 
Included     
(n=1269) 
not included 
(n=881) 
P-value 
Included   
(n=2980) 
not included 
(n=11752) 
P-value 
Smoking during 
pregnancy , n(%) 
      
  
 
   Never 1319 (75.6) 4648 (72.9) 
<0.001 
 
870 (69.4) 478 (64.2) 
0.055 
2434 (83.2) 7446 (71.4) 
<0.001 
   In the beginning of 
   pregnancy 
168 (9.6) 523 (8.2) 168 (13.4) 116 (15.6) 125 (4.3) 682 (6.5) 
   Continued  257 (14.7) 1208 (18.9) 216 (17.2) 151 (20.3) 367 (12.5) 2305 (22.1) 
Pre-pregnancy BMI, 
kg/m2, median (IQR) 
22.6 (20.8-25.2) 22.6 (20.7-25.5) 0.926 22.5 (20.8-25.0) 22.6 (20.7-25.3) 0.670 22.2 (20.5-24.4) 22.1 (20.4-24.4) 0.077 
 
P-value for differences calculated using Chi-square test for categorical variables, Student´s t‐test for continuous normal‐distributed variables, and Kruskal‐Wallis test for continuous non‐normal distributed variables. NA: not applicable.  
Numbers are based on unimputed data; percentages add up to 100% without taking into account missing values. 
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eTable 2 Continuous analysis of the association of maternal iodine status during pregnancy with 
child non-verbal and verbal IQ using standard linear regression models 
  
Non-verbal IQ verbal IQ 
Type of model 
Variables in the 
model  
Beta (95%CI) P-value Beta (95%CI) P-value 
linear model UI/Creat 0.602 (-0.007 to 1.210) 0.053 1.061 (0.450 to 1.672) 0.001 
non-linear model 
UI/Creat 0.632 (-5.848 to 7.113) 0.848 10.011 (3.499 to 16.523) 0.003 
UI/Creat^2 -0.003 (-0.651 to 0.644) 0.993 -0.898 (-1.549 to -0.247) 0.007 
 
Reported beta and 95%CI are increase in mean child IQ per natural log increase in UI/Creat. UI/Creat^2 refers to the addition of a squared 
logtransformed UI/Creat variable in the model. Analyses were performed using linear regression models. Analyses were adjusted for 
gestational age at urine sampling, child sex, maternal ethnicity/country of birth, maternal education, parity, maternal age, pre-pregnancy BMI, 
and smoking during pregnancy. 
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eFigure 1  Association of UI/Creat < 150 µg/g and UI/Creat ≥ 500 µg/g during pregnancy with 
child suboptimal non-verbal and verbal IQ.    
 
 
 
 
 
 
 
eFigure 1 Association of UI/Creat < 150 µg/g and UI/Creat ≥ 500 µg/g during pregnancy with child 
suboptimal non-verbal and verbal IQ.  
Figure shows the association of UI/Creat <150 µg/g (“deficiency”) with a) non-verbal IQ score <85 and c) verbal IQ score <85, and 
UI/Creat >=500 µg/g (“excess”) with b) non-verbal IQ score <85 and d) verbal IQ score <85 as compared to the reference group 
(UI/Creat ≥150 to <500 µg/g). Associations are depicted as effect estimate (dot) with 95%CI per cohort and overall as estimated by 
random-effects meta-analysis (diamond). Models are adjusted for gestational age, child sex, maternal ethnicity/country of birth, 
maternal education, parity, maternal age, pre-pregnancy BMI, smoking during pregnancy, child age and region in INMA.  
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eTable 3 Continuous analysis of the association of maternal iodine status during pregnancy with 
child verbal IQ stratified by tertile of gestational age using standard linear regression models. 
Type of model 
Variables in the 
model 
Gestational 
age (weeks) 
Beta (95%CI) P-value 
non-linear model 
UI/Creat 
≤12 
18.276 (6.923 to 29.628) 0.002 
UI/Creat^2 -1.786 (-2.953 to -0.620) 0.003 
Linear model  UI/Creat >12 and ≤14 1.333 (0.230 to 2.436) 0.018 
Linear model UI/Creat >14 0.444 (-0.601 to 1.489) 0.405 
 
Reported beta and 95%CI are increase in mean child verbal IQ per log increase in UI/Creat. UI/Creat^2 refers to the addition of a squared 
UI/Creat variable in the model. Analyses were performed using linear regression models. UI/Creat was transformed by the natural logarithm. 
Analyses were adjusted for gestational age at urine sampling, child sex, maternal ethnicity/country of birth, maternal education, parity, 
maternal age, pre-pregnancy BMI, and smoking during pregnancy. 
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eTable 4  Comparison of the ALSPAC study population included in the current study and in the 
previous publication of Bath et al. 2013  
 
 
this study cohort 
this study cohort 
restricted to ≤13 weeks 
gestation 
Bath et al. 2013 
No. 2980 1845 958 
gestational age, median 
(IQR) 
12 (8-16) 9 (7-11) 10 (9-12) 
UI/Creat, µg/g, median (IQR) 124 (82-199) 108 (75-161) 110 (74-170) 
UI/Creat < 150 µg/g , % 61.4 70.1 67.4 
UIC, µg/L, median (IQR) 96 (57-153) 96.8 (60-149) 91.1 (53.8-143) 
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eTable 5  Association of maternal iodine status with a child verbal IQ score in the lowest quartile 
as studied in the current ALSPAC study population and as in the previous publication of Bath et 
al. 2013  
 
this study cohort 
 
[OR (95%CI), P-value] 
this study cohort restricted  
to  ≤13 weeks gestation                
[OR (95%CI), P-value] 
Bath et al. 2013                                    
 
[OR (95%CI), P-value] 
1.13 (0.92 to 1.39), 0.259 1.42 (1.06 to 1.91), 0.019 1.58 (1.09 to 2.30), 0.02 
 
Reported OR and 95%CI for a verbal IQ score in the bottom quartile when exposed to a maternal UI/Creat < 150 µg/g vs ≥ 150 µg/g 
(reference group) during pregnancy. Analyses with un-imputed data were performed using logistic regression models and were adjusted as 
similarly as possible as compared to the fully adjusted model (model 3) as reported in the publication of Bath et al.  Analyses were adjusted 
for preterm birth, birthweight, child sex, maternal education, paternal education, maternal ethnicity (instead of child ethnicity), parity, age at 
delivery, smoking, maternal alcohol intake, breastfeeding, iron intake, and omega-3 fatty acid intake estimated from the Food Frequency 
Questionnaire completed at 32 weeks’ of gestation. Missing information that was corrected for in model 3 of Bath et al but lacking in the 
analysis of this study cohort, were: mothers parenting score (seven-factor measure of cognitive stimulation at 6 months of age), home 
observation for measurement of environment (HOME) score (six-factor measure of the emotional and cognitive environment at 6 months of 
age), the family adversity index (18-factor measure of hardship during pregnancy), life-event score (exposure to 41 stressful events during 
pregnancy), maternal depression since birth, fish-oil supplements during pregnancy, housing status, and crowding.  
 
